Molecular engineering of therapeutic cytokines

Antibodies

Volumn 2, Issue 3, 2013, Pages 426-451

  Vazquez Lombardi, Rodrigo ^a   Roome, Brendan ^a   Christ, Daniel ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Cytokines; Fusion proteins; Immunocytokines; Immunotherapy; Protein engineering

Indexed keywords

ACTINMMUNE; ALBINTERFERON; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; BETA1A INTERFERON; CD40 LIGAND; CINTREDEKIN BESUDOTOX; CONSENSUS INTERFERON; CYTOKINE; DENILEUKIN DIFTITOX; F16 IL2; GAMMA INTERFERON; GAMMA1B INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; KS IL2; L 19 12; NHS IL2; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PITRAKINRA; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 2; SELECTIKINE; TASONERMIN; TUCOTUZUMAB CELMOLEUKIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN ANTIBODY COMPLEX; BREAST CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CHRONIC GRANULOMATOUS DISEASE; CINCA SYNDROME; CUTANEOUS T CELL LYMPHOMA; CYTOKINE TOXICITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STABILITY; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HUMAN; HYPER IGM SYNDROME; IMMUNOMODULATION; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LYMPHOCYTOPENIA; MELANOMA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MULTIPLE SCLEROSIS; MUTAGENESIS; NATURAL KILLER CELL; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TOXICITY; WEGENER GRANULOMATOSIS;

EID: 84910634527     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2030426     Document Type: Review

References (160)

1. Dinarello, C. A. IL-1: Discoveries, controversies and future directions. Eur. J. Immunol. 2010, 40, 599-606.
2. Beeson, P. B. Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytes. J. Clin. Invest. 1948, 27, 524-524.
3. Morgan, D. A.; Ruscetti, F. W.; Gallo, R. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1976, 193, 1007-1008.
4. Gillis, S.; Smith, K. A. Long-term culture of tumor-specific cytotoxic T-cells. Nature 1977, 268, 154-156.
5. Gordon, J.; Maclean, L. D. A lymphocyte-stimulating factor produced in vitro. Nature 1965, 208, 795-796.
6. Isaacs, A.; Lindenmann, J. Virus interference. 1. The interferon. Proc. Royal Soc. B 1957, 147, 258-267.
7. Pestka, S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 2007, 282, 20047-20051.
8. Cantell, K.; Hirvonen, S.; Kauppinen, H. L.; Myllyla, G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol. 1981, 78, 29-38.
9. Goeddel, D. V.; Yelverton, E.; Ullrich, A.; Heyneker, H. L.; Miozzari, G.; Holmes, W.; Seeburg, P. H.; Dull, T.; May, L.; Stebbing, N.; et al. Human-leukocyte interferon produced by Escherichia-coli is biologically-active. Nature 1980, 287, 411-416.
10. Nagata, S.; Taira, H.; Hall, A.; Johnsrud, L.; Streuli, M.; Ecsodi, J.; Boll, W.; Cantell, K.; Weissmann, C. Synthesis in Escherichia-coli of a polypeptide with human-leukocyte interferon activity. Nature 1980, 284, 316-320.
11. Devos, R.; Plaetinck, G.; Cheroutre, H.; Simons, G.; Degrave, W.; Tavernier, J.; Remaut, E.; Fiers, W. Molecular-cloning of human interleukin-2 carrier DNA and its expression in Escherichia-coli. Nucleic Acids Res. 1983, 11, 4307-4323.
12. Taniguchi, T.; Matsui, H.; Fujita, T.; Takaoka, C.; Kashima, N.; Yoshimoto, R.; Hamuro, J. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983, 302, 305-310.
13. Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 2011, 22, 868-876.
14. Boyman, O.; Surh, C. D.; Sprent, J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin. Biol. Ther. 2006, 6, 1323-1331.
15. Atkins, M. B.; Lotze, M. T.; Dutcher, J. P.; Fisher, R. I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999, 17, 2105-2116.
16. Rosenberg, S. A.; Yang, J. C.; White, D. E.; Steinberg, S. M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2-Identification of the antigens mediating response. Ann. Surg. 1998, 228, 307-317.
17. Jevševar, S.; Kunstelj, M.; Porekar, V. G. PEGylation of therapeutic proteins. Biotechnol. J. 2010, 5, 113-128.
18. Harris, J. M.; Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2, 214-221.
19. Maack, T.; Johnson, V.; Kau, S. T.; Figueiredo, J.; Sigulem, D. Renal filtration, transport, and metabolism of low-molecular-weight proteins-Review. Kidney Int. 1979, 16, 251-270.
20. Crawford, J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapyinduced neutropenia. Semin. Oncol. 2003, 30, 24-30.
21. Bukowski, R. M.; Tendler, C.; Cutler, D.; Rose, E.; Laughlin, M. M.; Statkevich, P. Treating cancer with PEG intron-Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002, 95, 389-396.
22. Perry, C. M.; Jarvis, B. Peginterferon-alpha-2a (40kD)-A review of its use in the management of chronic hepatitis C. Drugs 2001, 61, 2263-2288.
23. Glue, P.; Fang, J. W. S.; Rouzier-Panis, R.; Raffanel, C.; Sabo, R.; Gupta, S. K.; Salfi, M.; Jacobs, S.; Hepatitis, C. I. T. G. Pegylated interferon-alpha 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 2000, 68, 556-567.
24. Yang, J. C.; Topalian, S. L.; Schwartzentruber, D. J.; Parkinson, D. R.; Marincola, F. M.; Weber, J. S.; Seipp, C. A.; White, D. E.; Rosenberg, S. A. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal-cell carcinoma and melanoma-A phase-I study and a randomised prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 1995, 76, 687-694.
25. Katre, N. V.; Knauf, M. J.; Laird, W. J. Chemical modification of recombinant interleukin-2 by polyethilene-glycol increases its potency in the murine Meth-A sarcoma model. Proc. Natl. Acad. Sci. USA 1987, 84, 1487-1491.
26. Klein, B.; Brailly, H. Cytokine-binding proteins-Stimulating antagonists. Immunol. Today 1995, 16, 216-220.
27. Sato, J.; Hamaguchi, N.; Doken, K.; Gotoh, K.; Ootsu, K.; Iwasa, S.; Ogawa, Y.; Toguchi, H. Enhancement of antitumor-activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal-antibody against rIL-2. Biotherapy 1993, 6, 225-231.
28. Rosenblum, M. G.; Unger, B. W.; Gutterman, J. U.; Hersh, E. M.; David, G. S.; Frincke, J. M. Modification of human-leukocyte interferon pharmacology with a monoclonal-antibody. Cancer Res. 1985, 45, 2421-2424.
29. Finkelman, F. D.; Madden, K. B.; Morris, S. C.; Holmes, J. M.; Boiani, N.; Katona, I. M.; Maliszewski, C. R. Anti-cytokine antibodies as carrier proteins-Prolongation of in-vivo effects of exogenous cytokines by injection of cytokine anti-cytokine antibody complexes. J. Immunol. 1993, 151, 1235-1244.
30. Boyman, O.; Kovar, M.; Rubinstein, M. P.; Surh, C. D.; Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311, 1924-1927.
31. Schein, C. H. The shape of the messenger: Using protein structure information to design novel cytokine-based therapeutics. Curr. Pharm. Des. 2002, 8, 2113-2129.
32. Boyman, O.; Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12, 180-190.
33. Krieg, C.; Letourneau, S.; Pantaleo, G.; Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl. Acad. Sci. USA 2010, 107, 11906-11911.
34. Tomala, J.; Chmelova, H.; Mrkvan, T.; Rihova, B.; Kovar, M. In Vivo Expansion of Activated Naive CD8(+) T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy. J. Immunol. 2009, 183, 4904-4912.
35. Kamimura, D.; Sawa, Y.; Sato, M.; Agung, E.; Hirano, T.; Murakami, M. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J. Immunol. 2006, 177, 306-314.
36. Webster, K. E.; Walters, S.; Kohler, R. E.; Mrkvan, T.; Boyman, O.; Surh, C. D.; Grey, S. T.; Sprent, J. In vivo expansion of T reg cells with IL-2-mAb complexes: Induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 2009, 206, 751-760.
37. Tang, Q.; Adams, J. Y.; Penaranda, C.; Melli, K.; Piaggio, E.; Sgouroudis, E.; Piccirillo, C. A.; Salomon, B. L.; Bluestone, J. A. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28, 687-697.
38. Liu, R.; Zhou, Q.; La Cava, A.; Campagnolo, D. I.; Van Kaer, L.; Shi, F.-D. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 2010, 40, 1577-1589.
39. Wilson, M. S.; Pesce, J. T.; Ramalingam, T. R.; Thompson, R. W.; Cheever, A.; Wynn, T. A. Suppression of Murine Allergic Airway Disease by IL-2: Anti-IL-2 Monoclonal Antibody-Induced Regulatory T Cells. J. Immunol. 2008, 181, 6942-6954.
40. Tam Nguyen, D.; Kyaw, T. S.; Kanellakis, P.; To, K.; Tipping, P.; Toh, B.-H.; Bobik, A.; Agrotis, A. Cytokine Therapy With Interleukin-2/Anti-Interleukin-2 Monoclonal Antibody Complexes Expands CD4+CD25+Foxp3+ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis. Circulation 2012, 126, 1256-1266.
41. Roopenian, D. C.; Akilesh, S. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7, 715-725.
42. Letourneau, S.; van Leeuwen, E. M.; Krieg, C.; Martin, C.; Pantaleo, G.; Sprent, J.; Surh, C. D.; Boyman, O. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl. Acad. Sci. USA 2010, 107, 2171-2176.
43. Carter, P. J. Introduction to current and future protein therapeutics: A protein engineering perspective. Exp. Cell Res. 2011, 317, 1261-1269.
44. Czajkowsky, D. M.; Hu, J.; Shao, Z.; Pleass, R. J. Fc-fusion proteins: New developments and future perspectives. EMBO Mol. Med. 2012, 4, 1015-1028.
45. Bitonti, A. J.; Dumont, J. A.; Low, S. C.; Peters, R. T.; Kropp, K. E.; Palombella, V. J.; Stattel, J. M.; Lu, Y. C.; Tan, C. A.; Song, J. J.; et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA 2004, 101, 9763-9768.
46. Dumont, J. A.; Bitonti, A. J.; Clark, D.; Evans, S.; Pickford, M.; Newman, S. P. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol Med. 2005, 18, 294-303.
47. Chang, C. H.; Gupta, P.; Goldenberg, D. M. Advances and challenges in developing cytokine fusion proteins as improved therapeutics. Expert Opin. Drug Discov. 2009, 4, 181-194.
48. Strohl, W. R. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr. Opin. Biotechnol. 2009, 20, 685-691.
49. Shoji-Hosaka, E.; Kobayashi, Y.; Wakitani, M.; Uchida, K.; Niwa, R.; Nakamura, K.; Shitara, K. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J. Biochem. (Tokyo) 2006, 140, 777-783.
50. Davis, P. M.; Abraham, R.; Xu, L.; Nadler, S. G.; Suchard, S. J. Abatacept binds to the fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007, 34, 2204-2210.
51. McGuire, H. M.; Walters, S.; Vogelzang, A.; Lee, C. M. Y.; Webster, K. E.; Sprent, J.; Christ, D.; Grey, S.; King, C. Interleukin-21 Is Critically Required in Autoimmune and Allogeneic Responses to Islet Tissue in Murine Models. Diabetes 2011, 60, 867-875.
52. Bubier, J. A.; Bennett, S. M.; Sproule, T. J.; Lyons, B. L.; Olland, S.; Young, D. A.; Roopenian, D. C. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. NY Acad. Sci. 2007, 1110, 590-601.
53. Young, D. A.; Hegen, M.; Margery Ma, H. L.; Whitters, M. J.; Albert, L. M.; Lowe, L.; Senices, M.; Wu, P. W.; Sibley, B.; Leathurby, Y.; et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007, 56, 1152-1163.
54. Feng, X. M.; Zheng, X. X.; Yi, S. N.; Lehnert, A. M.; Strom, T. B.; O'Connell, P. J. IL-10/Fc inhibits macrophage function and prolongs pancreatic islet xenograft survival. Transplantation 1999, 68, 1775-1783.
55. FloresVillanueva, P. O.; Zheng, X. X.; Strom, T. B.; Stadecker, M. J. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J. Immunol. 1996, 156, 3315-3320.
56. Zheng, X. X.; Steele, A. W.; Hancock, W. W.; Stevens, A. C.; Nickerson, P. W.; RoyChaudhury, P.; Tian, Y.; Strom, T. B. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J. Immunol. 1997, 158, 4507-4513.
57. Zheng, X. X.; Steele, A. W.; Nickerson, P. W.; Steurer, W.; Steiger, J.; Strom, T. B. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J. Immunol. 1995, 154, 5590-5600.
58. Schwager, K.; Kaspar, M.; Bootz, F.; Marcolongo, R.; Paresce, E.; Neri, D.; Trachsel, E. Preclinical characterization of Dekavil (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res. Ther. 2009, 11, Article No. R142.
59. Zheng, X. X.; Steele, A. W.; Hancock, W. W.; Kawamoto, K.; Li, X. C.; Nickerson, P. W.; Li, Y. S.; Tian, Y.; Strom, T. B. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J. Immunol. 1999, 163, 4041-4048.
60. Nam, H. J.; Song, M.-Y.; Choi, D.-H.; Yang, S.-H.; Jin, H.-T.; Sung, Y.-C. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur. J. Immunol. 2010, 40, 351-358.
61. Anderson, C. L.; Chaudhury, C.; Kim, J.; Bronson, C. L.; Wani, M. A.; Mohanty, S. Perspective-FcRn transports albumin: Relevance to immunology and medicine. Trends Immunol. 2006, 27, 343-348.
62. Osborn, B. L.; Gu, M.; Grzegorzewski, K. J.; Logan, T. F.; Crowder, K.; Weiss, G. R.; Syed, S.; Rowensky, E.; Tolcher, A.; Agarwala, S. S. Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein, in solid tumor patients. Proc. Amer. Assoc. Cancer Res. 2004, 2004, 1099.
63. Halpern, W.; Riccobene, T. A.; Agostini, H.; Baker, K.; Stolow, D.; Gu, M. L.; Hirsch, J.; Mahoney, A.; Carrell, J.; Boyd, E.; et al. Albugranin (TM), a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm. Res. 2002, 19, 1720-1729.
64. Nelson, D. R.; Benhamou, Y.; Chuang, W.-L.; Lawitz, E. J.; Rodriguez-Torres, M.; Flisiak, R.; Rasenack, J. W. F.; Kryczka, W.; Lee, C.-M.; Bain, V. G.; et al. Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-alpha in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3. Gastroenterology 2010, 139, 1267-1276.
65. Subramanian, G. M.; Fiscella, M.; Lamouse-Smith, A.; Zeuzem, S.; McHutchison, J. G. Albinterferon alpha-2b: A genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 2007, 25, 1411-1419.
66. Zeuzem, S.; Sulkowski, M. S.; Lawitz, E. J.; Rustgi, V. K.; Rodriguez-Torres, M.; Bacon, B. R.; Grigorescu, M.; Tice, A. D.; Lurie, Y.; Cianciara, J.; et al. Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-alpha in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1. Gastroenterology 2010, 139, 1257-1266.
67. Sung, C.; Nardelli, B.; LaFleur, D. W.; Blatter, E.; Corcoran, M.; Olsen, H. S.; Birse, C. E.; Pickeral, O. K.; Zhang, J.; Shah, D. An IFN-β-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J. Int. Cytokine Res. 2003, 23, 25-36.
68. Ward, E. S.; Gussow, D.; Griffiths, A. D.; Jones, P. T.; Winter, G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia-coli. Nature 1989, 341, 544-546.
69. Holt, L. J.; Basran, A.; Jones, K.; Chorlton, J.; Jespers, L. S.; Brewis, N. D.; Tomlinson, I. M. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 2008, 21, 283-288.
70. Walker, A.; Dunlevy, G.; Rycroft, D.; Topley, P.; Holt, L. J.; Herbert, T.; Davies, M.; Cook, F.; Holmes, S.; Jespers, L.; et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng. Des. Sel. 2010, 23, 271-278.
71. Qian, Z. M.; Li, H. Y.; Sun, H. Z.; Ho, K. Targeted drug delivery via the transferrin receptormediated endocytosis pathway. Pharmacol. Rev. 2002, 54, 561-587.
72. Daniels, T. R.; Delgado, T.; Helguera, G.; Penichet, M. L. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121, 159-176.
73. Daniels, T. R.; Delgado, T.; Rodriguez, J. A.; Helguera, G.; Penichet, M. L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 2006, 121, 144-158.
74. Kim, B.-J.; Zhou, J.; Martin, B.; Carlson, O. D.; Maudsley, S.; Greig, N. H.; Mattson, M. P.; Ladenheim, E. E.; Wustner, J.; Turner, A.; et al. Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides. J. Pharmacol. Exp. Ther. 2010, 334, 682-692.
75. Banerjee, D.; Flanagan, P. R.; Cluett, J.; Valberg, L. S. Transferrin receptors in the human gastrointestinal-tract-relationship to body iron stores. Gastroenterology 1986, 91, 861-869.
76. Bai, Y.; Ann, D. K.; Shen, W. C. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc. Natl. Acad. Sci. USA 2005, 102, 7292-7296.
77. Bai, Y.; Shen, W.-C. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm. Res. 2006, 23, 2116-2121.
78. Jones, S. A.; Rose-John, S. The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex. BBA-Mol. Cell Res. 2002, 1592, 251-263.
79. Rubinstein, M. P.; Kovar, M.; Purton, J. F.; Cho, J. H.; Boyman, O.; Surh, C. D.; Sprent, J. Converting IL-15 to a superagonist by binding to soluble IL-15R alpha. Proc. Natl. Acad. Sci. USA 2006, 103, 9166-9171.
80. Dubois, S.; Mariner, J.; Waldmann, T. A.; Tagaya, Y. IL-15R alpha recycles and presents IL-15 in trans to neighboring cells. Immunity 2002, 17, 537-547.
81. Waldmann, T. A. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6, 595-601.
82. Mortier, E.; Quemener, A.; Vusio, P.; Lorenzen, I.; Boublik, Y.; Grotzinger, J.; Plet, A.; Jacques, Y. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 2006, 281, 1612-1619.
83. Fischer, M.; Goldschmitt, J.; Peschel, C.; Brakenhoff, J. P.; Kallen, K. J.; Wollmer, A.; Grotzinger, J.; Rose-John, S. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 1997, 15, 142-145.
84. Pflanz, S.; Tacken, I.; Grotzinger, J.; Jacques, Y.; Dahmen, H.; Heinrich, P. C.; Muller-Newen, G. A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Lett. 1999, 450, 117-122.
85. Peters, M.; Blinn, G.; Jostock, T.; Schirmacher, P.; Zum Buschenfelde, K. H. M.; Galle, P. R.; Rose-John, S. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 2000, 119, 1663-1671.
86. Manoukian, G.; Hagemeister, F. Denileukin diftitox: A novel immunotoxin. Expert Opin. Biol. Ther. 2009, 9, 1445-1451.
87. Shimamura, T.; Husain, S. R.; Puri, R. K. The IL-4 and IL-13 pseudomonas exotoxins: New hope for brain tumor therapy. Neurosurg. Focus 2006, 20, E11-E11.
88. Foss, F. Clinical experience with denileukin diftitox (ONTAK). Semin. Oncol. 2006, 33, S11-S16.
89. Waters, C. A.; Schimke, P. A.; Snider, C. E.; Itoh, K.; Smith, K. A.; Nichols, J. C.; Strom, T. B.; Murphy, J. R. Interleukin-2 receptor-targeted cytotoxicity-Receptor-binding requirements for entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur. J. Immunol. 1990, 20, 785-791.
90. Bacha, P.; Williams, D. P.; Waters, C.; Williams, J. M.; Murphy, J. R.; Strom, T. B. Interleukin-2 receptor targeted cyto-toxicity interleukin-2 receptor mediated action of a diphtheria-toxin related interleukin-2 fusion protein. J. Exp. Med. 1988, 167, 612-622.
91. Olsen, E.; Duvic, M.; Frankel, A.; Kim, Y.; Martin, A.; Vonderheid, E.; Jegasothy, B.; Wood, G.; Gordon, M.; Heald, P.; et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 2001, 19, 376-388.
92. Ruddle, J. B.; Harper, C. A.; Honemann, D.; Seymour, J. F.; Prince, H. M.; Harper, C. A. A denileukin diftitox (Ontak) associated retinopathy? Br. J. Ophthalmol. 2006, 90, 1070-1071.
93. Ruddle, J. B.; Prince, H. M. Denileukin diftitox and vision loss. Leuk. Lymphoma 2007, 48, 655-656.
94. Takeuchi, M.; Keino, H.; Kezuka, T.; Usui, M.; Taguchi, O. Immune responses to retinal selfantigens in CD25(+)CD4(+) regulatory T-Cell-depleted mice. Invest. Ophthalmol. Visual Sci. 2004, 45, 1879-1886.
95. Iwamoto, F. M.; Lamborn, K. R.; Robins, H. I.; Mehta, M. P.; Chang, S. M.; Butowski, N. A.; DeAngelis, L. M.; Abrey, L. E.; Zhang, W.-T.; Prados, M. D.; et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-Oncology 2010, 12, 855-861.
96. Mut, M.; Sherman, J. H.; Shaffrey, M. E.; Schiff, D. Cintredekin besudotox in treatment of malignant glioma. Expert Opin. Biol. Ther. 2008, 8, 805-812.
97. Jackaman, C.; Bundell, C. S.; Kinnear, B. F.; Smith, A. M.; Filion, P.; van Hagen, D.; Robinson, B. W. S.; Nelson, D. J. IL-2 intratumoral immunotherapy enhances CD8(+) T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2(1). J. Immunol. 2003, 171, 5051-5063.
98. Gutbrodt, K. L.; Neri, D. Immunocytokines. Antibodies 2012, 1, 70-87.
99. van Horssen, R.; ten Hagen, T. L. M.; Eggermont, A. M. M. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11, 397-408.
100. Sondel, P. M.; Gillies, S. D. Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies 2012, 1, 149-171.
101. Kontermann, R. E. Antibody-cytokine fusion proteins. Arch. Biochem. Biophys. 2012, 526, 194-205.
102. Pasche, N.; Neri, D. Immunocytokines: A novel class of potent armed antibodies. Drug Discov. Today 2012, 17, 583-590.
103. Connor, J. P.; Cristea, M. C.; Lewis, N. L.; Lewis, L. D.; Komarnitsky, P. B.; Mattiacci, M. R.; Felder, M.; Stewart, S.; Harter, J.; Henslee-Downey, J.; et al. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAMpositive advanced solid tumors. BMC Cancer 2013, 13, Article No. 20.
104. Patriarca, C.; Macchi, R. M.; Marschner, A. K.; Mellstedt, H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat. Rev. 2012, 38, 68-75.
105. Albertini, M. R.; Hank, J. A.; Gadbaw, B.; Kostlevy, J.; Haldeman, J.; Schalch, H.; Gan, J.; Kim, K.; Eickhoff, J.; Gillies, S. D.; et al. Phase II trial of hu14. 18-IL2 for patients with metastatic melanoma. Cancer Immunol. Immunother. 2012, 61, 2261-2271.
106. Mujoo, K.; Cheresh, D. A.; Yang, H. M.; Reisfeld, R. A. Disialoganglioside-GD2 on human neuroblastoma-cells-Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor-growth. Cancer Res. 1987, 47, 1098-1104.
107. Yamane, B. H.; Hank, J. A.; Albertini, M. R.; Sondel, P. M. The development of antibody-IL-2 based immunotherapy with hu14. 18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin. Investig. Drugs 2009, 18, 991-1000.
108. Helguera, G.; Rodriguez, J. A.; Penichet, M. L. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol. Cancer Ther. 2006, 5, 1029-1040.
109. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; Press, M. F. Studies of the HER-2/neu proto-oncogene in human-breast and ovarian-cancer. Science 1989, 244, 707-712.
110. Gillies, S. D.; Lan, Y.; Williams, S.; Carr, F.; Forman, S.; Raubitschek, A.; Lo, K. M. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 2005, 105, 3972-3978.
111. Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; Stein, R.; Chang, C.-H. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009, 114, 3864-3871.
112. Hirsch, B.; Brauer, J.; Fischdick, M.; Loddenkemper, C.; Bulfone-Paus, S.; Stein, H.; Duerkop, H. Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo. Curr. Drug Targets 2009, 10, 110-117.
113. Frey, K.; Fiechter, M.; Schwager, K.; Belloni, B.; Barysch, M. J.; Neri, D.; Dummer, R. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp. Dermatol. 2011, 20, 685-688.
114. Kriegsmann, J.; Berndt, A.; Hansen, T.; Borsi, L.; Zardi, L.; Brauer, R.; Petrow, P. K.; Otto, M.; Kirkpatrick, C. J.; Gay, S.; et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol. Int. 2004, 24, 25-33.
115. Schliemann, C.; Wiedmer, A.; Pedretti, M.; Szczepanowski, M.; Klapper, W.; Neri, D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk. Res. 2009, 33, 1718-1722.
116. Gillessen, S.; Gnad-Vogt, U. S.; Gallerani, E.; Beck, J.; Sessa, C.; Omlin, A.; Mattiacci, M. R.; Liedert, B.; Kramer, D.; Laurent, J.; et al. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur. J. Cancer 2013, 49, 35-44.
117. Epstein, A. L.; Chen, F. M.; Taylor, C. R. A novel method for the detection of necrotic lesions in human cancers. Cancer Res. 1988, 48, 5842-5848.
118. Holliger, P.; Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23, 1126-1136.
119. Naramura, M.; Gillies, S. D.; Mendelsohn, J.; Reisfeld, R. A.; Mueller, B. M. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody IL2 fusion protein against humanmelanoma cells. Immunol. Lett. 1993, 39, 91-99.
120. Jain, R. K.; Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal-antibodies and other macromolecules in tumors-Significance of elevated interstitial pressure. Cancer Res. 1988, 48, 7022-7032.
121. Yokota, T.; Milenic, D. E.; Whitlow, M.; Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992, 52, 3402-3408.
122. Milenic, D. E.; Yokota, T.; Filpula, D. R.; Finkelman, M. A. J.; Dodd, S. W.; Wood, J. F.; Whitlow, M.; Snoy, P.; Schlom, J. Construction, binding-properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal-antibody CC49. Cancer Res. 1991, 51, 6363-6371.
123. Adams, G. P.; Schier, R.; McCall, A. M.; Crawford, R. S.; Wolf, E. J.; Weiner, L. M.; Marks, J. D. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 1998, 77, 1405-1412.
124. Rossi, E. A.; Rossi, D. L.; Stein, R.; Goldenberg, D. M.; Chang, C.-H. A Bispecific Antibody-IFN alpha 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells. Cancer Res. 2010, 70, 7600-7609.
125. Kontermann, R. E. Dual targeting strategies with bispecific antibodies. mAbs 2012, 4, 182-197.
126. Bremer, E.; de Bruyn, M.; Wajant, H.; Helfrich, W. Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family. Curr. Drug Targets 2009, 10, 94-103.
127. Galeazzi, M.; Baldi, C.; Prisco, E.; Bardelli, M.; Neri, D.; Giovannoni, L.; Selvi, E.; Caporali, R. A Phase Ib Clinical Trial with F8-IL10, an Anti-Inflammatory Immunocytokine for the Treatment of Rheumatoid Arthritis (RA), Used in Combination with Methotrexate (MTX). Arthritis Rheum. 2012, 64, S553-S554.
128. ReidhaarOlson, J. F.; DeSouzaHart, J. A.; Selick, H. E. Identification of residues critical to the activity of human granulocyte colony-stimulating factor. Biochemistry (Mosc.) 1996, 35, 9034-9041.
129. Young, D. C.; Zhan, H. J.; Cheng, Q. L.; Hou, J. Z.; Matthews, D. J. Characterization of the receptor binding determinants of granulocyte colony stimulating factor. Protein Sci. 1997, 6, 1228-1236.
130. Collins, L.; Tsien, W. H.; Seals, C.; Hakimi, J.; Weber, D.; Bailon, P.; Hoskings, J.; Greene, W. C.; Toome, V.; Ju, G. Identification of specific residues of human interleukin-2 that affect binding to the 70-kDa subunit (p70) of the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA 1988, 85, 7709-7713.
131. Ju, G.; Collins, L.; Kaffka, K. L.; Tsien, W. H.; Chizzonite, R.; Crowl, R.; Bhatt, R.; Kilian, P. L. Structure-function analysis of human interleukin-2-Identification of amino-acid-residues required for biological-activity. J. Biol. Chem. 1987, 262, 5723-5731.
132. Weir, M. P.; Chaplin, M. A.; Wallace, D. M.; Dykes, C. W.; Hobden, A. N. Structure activity relationships of recombinant human interleukin-2. Biochemistry (Mosc.) 1988, 27, 6883-6892.
133. Lee, C. M. Y.; McGuire, H.; Basten, A.; King, C.; Christ, D. Expression, purification and characterization of recombinant interleukin-21. J. Immunol. Methods 2010, 362, 185-189.
134. Marshall, S. A.; Lazar, G. A.; Chirino, A. J.; Desjarlais, J. R. Rational design and engineering of therapeutic proteins. Drug Discov. Today 2003, 8, 212-221.
135. Lowe, D.; Dudgeon, K.; Rouet, R.; Schofield, P.; Jermutus, L.; Christ, D. Aggregation, stability, and formulation of human antibody therapeutics. Adv. Protein Chem. Struct. Biol. 2011, 84, 41-61.
136. Dudgeon, K.; Rouet, R.; Kokmeijer, I.; Schofield, P.; Stolp, J.; Langley, D.; Stock, D.; Christ, D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc. Natl. Acad. Sci. USA 2012, 109, 10879-10884.
137. Arakawa, T.; Prestrelski, S. J.; Narhi, L. O.; Boone, T. C.; Kenney, W. C. Cysteine-17 of recombinant human granulocyte-colony-stimulating factor is partially solvent-exposed. J. Protein Chem. 1993, 12, 525-531.
138. Doyle, M. V.; Lee, M. T.; Fong, S. Comparison of the biological-activities of human recombinant interleukin-2125 and native interleukin-2. J. Biol. Response Mod. 1985, 4, 96-109.
139. Lin, L. Betaseron. Dev. Biol. Stand. 1998, 96, 97-104.
140. Bishop, B.; Koay, D. C.; Sartorelli, A. C.; Regan, L. Reengineering granulocyte colonystimulating factor for enhanced stability. J. Biol. Chem. 2001, 276, 33465-33470.
141. Luo, P.; Hayes, R. J.; Chan, C.; Stark, D. M.; Hwang, M. Y.; Jacinto, J. M.; Juvvadi, P.; Chung, H. S.; Kundu, A.; Ary, M. L.; et al. Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Sci. 2002, 11, 1218-1226.
142. Tang, L.; Persky, A. M.; Hochhaus, G.; Meibohm, B. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 2004, 93, 2184-2204.
143. French, A. R.; Lauffenburger, D. A. Controlling receptor/ligand trafficking: Effects of cellular and molecular properties on endosomal sorting. Ann. Biomed. Eng. 1997, 25, 690-707.
144. Lauffenburger, D. A.; Fallon, E. M.; Haugh, J. M. Scratching the (cell) surface: Cytokine engineering for improved ligand/receptor trafficking dynamics. Chem. Biol. 1998, 5, R257-R263.
145. Fallon, E. M.; Liparoto, S. F.; Lee, K. J.; Ciardelli, T. L.; Lauffenburger, D. A. Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog. J. Biol. Chem. 2000, 275, 6790-6797.
146. Sarkar, C. A.; Lowenhaupt, K.; Horan, T.; Boone, T. C.; Tidor, B.; Lauffenburger, D. A. Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat. Biotechnol. 2002, 20, 908-913.
147. Rao, B. M.; Driver, I.; Lauffenburger, D. A.; Wittrup, K. D. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry (Mosc.) 2005, 44, 10696-10701.
148. Rao, B. M.; Girvin, A. T.; Ciardelli, T.; Lauffenburger, D. A.; Wittrup, K. D. Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng. 2003, 16, 1081-1087.
149. Liu, D. V.; Maier, L. M.; Hafler, D. A.; Wittrup, K. D. Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells. J. Immunother. 2009, 32, 887-894.
150. Levin, A. M.; Bates, D. L.; Ring, A. M.; Krieg, C.; Lin, J. T.; Su, L.; Moraga, I.; Raeber, M. E.; Bowman, G. R.; Novick, P.; et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484, 529-533.
151. Junttila, I. S.; Creusot, R. J.; Moraga, I.; Bates, D. L.; Wong, M. T.; Alonso, M. N.; Suhoski, M. M.; Lupardus, P.; Meier-Schellersheim, M.; Engleman, E. G.; et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 2012, 8, 990-998.
152. Hershey, G. K. K. IL-13 receptors and signaling pathways: An evolving web. J. Allergy Clin. Immunol. 2003, 111, 677-690.
153. Antoniu, S. A. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr. Opin. Investig. Drugs 2010, 11, 1286-1294.
154. Antoniu, S. A.; Cojocaru, I. Pitrakinra for asthma. Expert Opin. Biol. Ther. 2010, 10, 1609-1615.
155. Wenzel, S.; Wilbraham, D.; Fuller, R.; Burmeister Getz, E.; Lonphre, M. Effect of an interieukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 2007, 370, 1422-1431.
156. Tony, H. P.; Shen, B. J.; Reusch, P.; Sebald, W. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high-efficiency. Eur. J. Biochem. 1994, 225, 659-665.
157. Malara, N.; Foca, D.; Casadonte, F.; Sesto, M.; Paolino, D.; Tassone, P.; Venuta, S.; Savino, R. Treatment with an adenoviral vector expressing the IL-6 receptor superantagonist sant7 compared with the treatment with the recombinant sant7 protein in MM cell lines. J. Immunother. 2006, 29, 674-675.
158. Tassone, P.; Neri, P.; Burger, R.; Savino, R.; Shammas, M.; Catley, L.; Podar, K.; Chauhan, D.; Masciari, S.; Gozzini, A.; et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin. Cancer Res. 2005, 11, 4251-4258.
159. Gallelli, L.; Falcone, D.; Pelaia, G.; Renda, T.; Terracciano, R.; Malara, N.; Vatrella, A.; Sanduzzi, A.; D'Agostino, B.; Rossi, F.; et al. Interleukin-6 receptor superantagonist Sant7 inhibits TGF-beta-induced proliferation of human lung fibroblasts. Cell Prolif. 2008, 41, 393-407.
160. Savino, R.; Ciapponi, L.; Lahm, A.; Demartis, A.; Cabibbo, A.; Toniatti, C.; Delmastro, P.; Altamura, S.; Ciliberto, G. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 1994, 13, 5863-5870.